Literature DB >> 34244153

Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Naoko Sasamoto1, Ana Babic2, Allison F Vitonis3, Linda Titus4, Daniel W Cramer3,5, Britton Trabert6, Shelley S Tworoger5,7, Kathryn L Terry3,5.   

Abstract

Menstrual pain has been associated with increased ovarian cancer risk, presumably through increased inflammation, which is known to play a critical role in ovarian carcinogenesis. Analgesic medications are frequently used to treat menstrual pain, some of which lower ovarian cancer risk. In this study, we examined the association between analgesic use for menstrual pain during the premenopausal period and ovarian cancer risk among women with history of menstrual pain. We used data from the New England Case-Control Study, including 1,187 epithelial ovarian cancer cases and 1,225 population-based controls enrolled between 1998 and 2008 with detailed information on analgesic use for their menstrual pain. We used unconditional logistic regression to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between analgesic use (i.e., aspirin, ibuprofen, acetaminophen) for menstrual pain and ovarian cancer risk. We further conducted a stratified analysis by intensity of menstrual pain (mild/moderate, severe). Among women with menstrual pain during their 20s and 30s, ever use of analgesics for menstrual pain was not significantly associated with ovarian cancer risk. However, among women with severe menstrual pain, ever use of aspirin or acetaminophen for menstrual pain was inversely associated with risk (OR, 0.41; 95% CI, 0.18-0.94 and OR, 0.43; 95% CI, 0.21-0.88 compared with never users, respectively). No significant association was observed between analgesic use and ovarian cancer risk among women with mild/moderate menstrual pain (P interaction ≤ 0.03). Our results suggest that use of aspirin or acetaminophen for severe menstrual pain may be associated with lower risk of ovarian cancer. PREVENTION RELEVANCE: This study investigates whether analgesic use specifically for menstrual pain during the premenopausal period influences ovarian cancer risk. Our results suggest use of aspirin or acetaminophen for severe menstrual pain may be associated with lower risk of ovarian cancer among women with severe menstrual pain. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244153      PMCID: PMC8344407          DOI: 10.1158/1940-6207.CAPR-21-0090

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  39 in total

1.  High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.

Authors:  Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Res       Date:  2019-08-28       Impact factor: 12.701

2.  The woman at risk for developing ovarian cancer.

Authors:  L McGowan; L Parent; W Lednar; H J Norris
Journal:  Gynecol Oncol       Date:  1979-06       Impact factor: 5.482

3.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

Review 4.  Mechanism of action of acetaminophen: is there a cyclooxygenase 3?

Authors:  R M Botting
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

Review 5.  Possible role of ovarian epithelial inflammation in ovarian cancer.

Authors:  R B Ness; C Cottreau
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

6.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.

Authors:  Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

7.  The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Britton Trabert; Shelley S Tworoger; Katie M O'Brien; Mary K Townsend; Renée T Fortner; Edwin S Iversen; Patricia Hartge; Emily White; Pilar Amiano; Alan A Arslan; Leslie Bernstein; Louise A Brinton; Julie E Buring; Laure Dossus; Gary E Fraser; Mia M Gaudet; Graham G Giles; Inger T Gram; Holly R Harris; Judith Hoffman Bolton; Annika Idahl; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Marina Kvaskoff; James V Lacey; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Kim Overvad; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Elio Riboli; Kim Robien; Thomas E Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Veronica W Setiawan; Anthony J Swerdlow; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Anne Zeleniuch-Jacquotte; Nicolas Wentzensen
Journal:  Cancer Res       Date:  2020-01-13       Impact factor: 12.701

Review 8.  Prostaglandin receptors are mediators of vascular function in endometrial pathologies.

Authors:  Henry N Jabbour; Kurt J Sales; Oliver P Milling Smith; Sharon Battersby; Sheila C Boddy
Journal:  Mol Cell Endocrinol       Date:  2006-05-15       Impact factor: 4.102

9.  Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

Authors:  Nicolas Wentzensen; Elizabeth M Poole; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Lesley M Butler; Saioa Chamosa; Tess V Clendenen; Laure Dossus; Renee Fortner; Susan M Gapstur; Mia M Gaudet; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Michael Jones; Rudolf Kaaks; Victoria Kirsh; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Louise K Sjöholm; Sabina Sieri; Anthony Swerdlow; Anna Tjonneland; Ruth Travis; Antonia Trichopoulou; Piet A van den Brandt; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

10.  Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.

Authors:  Katarina Rask; Yihong Zhu; Wanzhong Wang; Lars Hedin; Karin Sundfeldt
Journal:  Mol Cancer       Date:  2006-11-16       Impact factor: 27.401

View more
  1 in total

Review 1.  Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.

Authors:  Lauren Clarfield; Laura Diamond; Michelle Jacobson
Journal:  Curr Oncol       Date:  2022-03-21       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.